financetom
Business
financetom
/
Business
/
Stifel Financial Q2 revenue up 5%, beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stifel Financial Q2 revenue up 5%, beats estimates
Jul 30, 2025 4:48 AM

Overview

* Stifel Q2 revenue rises 5% yr/yr, beating analyst expectations, per LSEG data

* Non-GAAP net income for Q2 beats analyst estimates, reflecting strong performance

* Co repurchased $83 mln of common stock during the quarter

Outlook

* Company confident about second half of 2025 and beyond

Result Drivers

* TRANSACTIONAL REVENUES - Increased 11% over the year-ago quarter, contributing to overall revenue growth

* ASSET MANAGEMENT - Revenues rose 6% yr/yr, driven by higher asset values and net new asset growth

* FINANCIAL ADVISORS - Added 82 advisors, marking the strongest recruiting quarter in a decade

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $1.28 $1.24

Revenue bln bln (5

Analysts

)

Q2 $1.71

Adjusted

EPS

Q2 EPS $1.34

Q2 Beat $185.60 $176.10

Adjusted mln mln (4

Net Analysts

Income )

Q2 Net $145.73

Income mln

Q2 ROCE 15.2%

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the investment banking & brokerage services peer group is "buy."

* Wall Street's median 12-month price target for Stifel Financial Corp ( SF ) is $117.50, about 6.3% above its July 29 closing price of $110.09

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Indian news agency ANI sues Netflix for using its content in hijack drama
Indian news agency ANI sues Netflix for using its content in hijack drama
Sep 9, 2024
NEW DELHI, Sept 9 (Reuters) - Indian news agency ANI has sued Netflix Inc ( NFLX ) and producers of an Indian series about a plane hijack, asking for four episodes to be taken down as they used ANI content without permission, ANI's lawyer told Reuters on Monday. The series, called IC-814: The Kandahar Hijack - a fictionalised version of...
LVMH names UK designer Sarah Burton Givenchy creative director
LVMH names UK designer Sarah Burton Givenchy creative director
Sep 9, 2024
* Burton is former Alexander McQueen designer * Designed Kate Middleton's 2011 wedding dress (Adds industry context in paragraphs 6-8, background on CEO in paragraphs 11-12) By Mimosa Spencer PARIS, Sept 9 (Reuters) - French luxury goods company LVMH named on Monday Sarah Burton, the longtime-Alexander McQueen designer behind the Princess of Wales' 2011 wedding dress, as the new creative...
Methanex to Acquire OCI Global's International Methanol Business for $2.05 Billion
Methanex to Acquire OCI Global's International Methanol Business for $2.05 Billion
Sep 9, 2024
04:26 AM EDT, 09/09/2024 (MT Newswires) -- Methanex ( MEOH ) said Sunday it has agreed to acquire the international methanol business of OCI Global for $2.05 billion. The deal includes OCI's interest in two methanol facilities in Beaumont, Texas, as well as a low-carbon methanol business and an idled facility in the Netherlands. The company expects to generate $30...
Summit Therapeutics' Trial Shows Ivonescimab Significantly Improved Progression-Free Survival Compared With Pembrolizumab
Summit Therapeutics' Trial Shows Ivonescimab Significantly Improved Progression-Free Survival Compared With Pembrolizumab
Sep 9, 2024
04:54 AM EDT, 09/09/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Sunday that data from the primary analysis of the phase 3 HARMONi-2 trial showed that ivonescimab monotherapy has a statistically significant improvement in progression-free survival compared with pembrolizumab monotherapy as a first-line treatment in patients with non-small cell lung cancer. The data for the trial, which took...
Copyright 2023-2026 - www.financetom.com All Rights Reserved